Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study
Abstract Objective The Diabetes Prevention Program (DPP) is the gold standard lifestyle modification program that reduces incident type 2 diabetes mellitus. Patients with prediabetes and patients with non‐alcoholic fatty liver disease (NAFLD) often share metabolic features; we hypothesized that the...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | Obesity Science & Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/osp4.637 |
| _version_ | 1797810435945136128 |
|---|---|
| author | Melissa Hershman Karen Torbjornsen Daniel Pang Brooke Wyatt Douglas T. Dieterich Ponni V. Perumalswami Andrea D. Branch Amreen M. Dinani |
| author_facet | Melissa Hershman Karen Torbjornsen Daniel Pang Brooke Wyatt Douglas T. Dieterich Ponni V. Perumalswami Andrea D. Branch Amreen M. Dinani |
| author_sort | Melissa Hershman |
| collection | DOAJ |
| description | Abstract Objective The Diabetes Prevention Program (DPP) is the gold standard lifestyle modification program that reduces incident type 2 diabetes mellitus. Patients with prediabetes and patients with non‐alcoholic fatty liver disease (NAFLD) often share metabolic features; we hypothesized that the DPP could be adapted and used to improve outcomes in patients with NAFLD. Methods NAFLD patients were recruited into a 1 year modified DPP. Demographics, medical comorbidities, and clinical laboratory values were collected at baseline, 6 and 12 months. The primary endpoint was change in weight at 12 months. Secondary endpoints were changes in hepatic steatosis, metabolic comorbidities, and liver enzymes (per‐protocol basis) and retention at 6 and 12 months. Results Fourteen NAFLD patients enrolled; three dropped out before 6 months. From baseline to 12 months, hepatic steatosis (p = 0.03), alanine aminotransferase (p = 0.02), aspartate aminotransferase (p = 0.02), high‐density lipoprotein (p = 0.01) and NAFLD fibrosis score (p < 0.001) improved, but low‐density lipoprotein worsened (p = 0.04). Conclusion Seventy‐nine percent of patients completed the modified DPP. Patients lost weight and had improvements in five out of six indicators of liver injury and lipid metabolism. Clinical Trial Registry Number NCT04988204. |
| first_indexed | 2024-03-13T07:08:46Z |
| format | Article |
| id | doaj.art-8d7dfc381c51418a8726558e99503cb6 |
| institution | Directory Open Access Journal |
| issn | 2055-2238 |
| language | English |
| last_indexed | 2024-03-13T07:08:46Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Obesity Science & Practice |
| spelling | doaj.art-8d7dfc381c51418a8726558e99503cb62023-06-06T06:00:56ZengWileyObesity Science & Practice2055-22382023-06-019321822510.1002/osp4.637Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot studyMelissa Hershman0Karen Torbjornsen1Daniel Pang2Brooke Wyatt3Douglas T. Dieterich4Ponni V. Perumalswami5Andrea D. Branch6Amreen M. Dinani7Division of Gastroenterology, Oregon Health & Science University Portland Oregon USAIcahn School of Medicine at Mount Sinai New York New York USADepartment of Medicine Icahn School of Medicine at Mount Sinai New York New York USAIcahn School of Medicine at Mount Sinai New York New York USADivision of Liver Diseases Icahn School of Medicine at Mount Sinai New York New York USADivision of Liver Diseases Icahn School of Medicine at Mount Sinai New York New York USADivision of Liver Diseases Icahn School of Medicine at Mount Sinai New York New York USADivision of Liver Diseases Icahn School of Medicine at Mount Sinai New York New York USAAbstract Objective The Diabetes Prevention Program (DPP) is the gold standard lifestyle modification program that reduces incident type 2 diabetes mellitus. Patients with prediabetes and patients with non‐alcoholic fatty liver disease (NAFLD) often share metabolic features; we hypothesized that the DPP could be adapted and used to improve outcomes in patients with NAFLD. Methods NAFLD patients were recruited into a 1 year modified DPP. Demographics, medical comorbidities, and clinical laboratory values were collected at baseline, 6 and 12 months. The primary endpoint was change in weight at 12 months. Secondary endpoints were changes in hepatic steatosis, metabolic comorbidities, and liver enzymes (per‐protocol basis) and retention at 6 and 12 months. Results Fourteen NAFLD patients enrolled; three dropped out before 6 months. From baseline to 12 months, hepatic steatosis (p = 0.03), alanine aminotransferase (p = 0.02), aspartate aminotransferase (p = 0.02), high‐density lipoprotein (p = 0.01) and NAFLD fibrosis score (p < 0.001) improved, but low‐density lipoprotein worsened (p = 0.04). Conclusion Seventy‐nine percent of patients completed the modified DPP. Patients lost weight and had improvements in five out of six indicators of liver injury and lipid metabolism. Clinical Trial Registry Number NCT04988204.https://doi.org/10.1002/osp4.637diabetes prevention programlifestyle interventionnonalcoholic fatty liver diseaseweight loss |
| spellingShingle | Melissa Hershman Karen Torbjornsen Daniel Pang Brooke Wyatt Douglas T. Dieterich Ponni V. Perumalswami Andrea D. Branch Amreen M. Dinani Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study Obesity Science & Practice diabetes prevention program lifestyle intervention nonalcoholic fatty liver disease weight loss |
| title | Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study |
| title_full | Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study |
| title_fullStr | Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study |
| title_full_unstemmed | Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study |
| title_short | Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study |
| title_sort | modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease a pilot study |
| topic | diabetes prevention program lifestyle intervention nonalcoholic fatty liver disease weight loss |
| url | https://doi.org/10.1002/osp4.637 |
| work_keys_str_mv | AT melissahershman modificationofthediabetespreventionprogramforthetreatmentofnonalcoholicfattyliverdiseaseapilotstudy AT karentorbjornsen modificationofthediabetespreventionprogramforthetreatmentofnonalcoholicfattyliverdiseaseapilotstudy AT danielpang modificationofthediabetespreventionprogramforthetreatmentofnonalcoholicfattyliverdiseaseapilotstudy AT brookewyatt modificationofthediabetespreventionprogramforthetreatmentofnonalcoholicfattyliverdiseaseapilotstudy AT douglastdieterich modificationofthediabetespreventionprogramforthetreatmentofnonalcoholicfattyliverdiseaseapilotstudy AT ponnivperumalswami modificationofthediabetespreventionprogramforthetreatmentofnonalcoholicfattyliverdiseaseapilotstudy AT andreadbranch modificationofthediabetespreventionprogramforthetreatmentofnonalcoholicfattyliverdiseaseapilotstudy AT amreenmdinani modificationofthediabetespreventionprogramforthetreatmentofnonalcoholicfattyliverdiseaseapilotstudy |